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a  b  s  t  r  a  c  t
A  biosimilar  is  a biologic  that  is highly  similar  to  a licensed  biologic  (the  reference  product)  in terms  of
purity,  safety  and  efﬁcacy.  If the reference  product  is  licensed  to treat multiple  therapeutic  indications,
extrapolation  of  indications,  i.e.,  approval  of  a biosimilar  for  use  in  an indication  held  by  the  referenceccepted 13 June 2016
eywords:
ancer
xtrapolation
iosimilar
product  but  not  directly  studied  in a comparative  clinical  trial  with  the biosimilar,  may  be possible  but has
to  be scientiﬁcally  justiﬁed.  Here,  we  describe  the  data  required  to establish  biosimilarity  and  emphasize
that  indication  extrapolation  is based  on  scientiﬁc  principles  and  known  mechanism  of action.
© 2016  The  Authors  and  Pﬁzer  Inc.  Published  by Elsevier  Ireland  Ltd.  This is an  open  access  article
under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).onoclonal antibody
. Introduction
Biologics are essential and widely used in cancer treatment as
herapeutic agents (e.g., monoclonal antibodies [mAbs]) and as sup-
ortive care agents (e.g., growth factors). Because biologics are
nherently variable complex molecules that are produced through
∗ Corresponding author.
E-mail addresses: ira.jacobs@pﬁzer.com, iraallenjacobs@aol.com (I. Jacobs).
ttp://dx.doi.org/10.1016/j.critrevonc.2016.06.002
040-8428/© 2016 The Authors and Pﬁzer Inc. Published by Elsevier Ireland Ltd. This is an
icenses/by-nc-nd/4.0/).manufacturing processes in living cells, they cannot be dupli-
cated identically to a level typically possible for small-molecule
drugs. Hence, the term “biosimilar” is used to describe a biologic
that is highly similar to a licensed biologic product (the refer-
ence product) (European Medicines Agency, 2014; US Food and
Drug Administration, 2015; World Health Organization, 2009).
Because biosimilars are produced in living cells, differences may
occur due to post-translational modiﬁcations (e.g., glycosylation) or
altered higher order structure (protein folding and protein-protein
interactions) that may  affect the clinical outcome. Most of these
 open access article under the CC BY-NC-ND license (http://creativecommons.org/
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ifferences can be detected with state-of-the-art analytical meth-
ds, but not all. Therefore, the approval of any biosimilar has to be
ased upon the overall assessment of biosimilarity to the reference
roduct through robust analytical, non-clinical and clinical studies
hat demonstrate that the proposed biosimilar and the reference
roduct are highly similar and there are no clinically meaningful
ifferences between the two products in terms of purity, safety
nd efﬁcacy (European Medicines Agency, 2014; US Food and Drug
dministration, 2015; World Health Organization, 2009). Variabil-
ty in post-translational modiﬁcations also exist between different
atches of the reference product but because they do not alter
he clinical proﬁle they are acceptable by the regulatory bodies
Schiestl et al., 2011).
High-quality, safe, and effective biosimilars have the potential
o increase access to biologic therapies worldwide and to reduce
ancer care costs. Despite the stringent process outlined by several
egulatory bodies around the world for the approval of biosimi-
ars, some clinicians may  hesitate to use biosimilars, particularly
n therapeutic indications that have been licensed based on data
xtrapolation, i.e., approved for use in an indication held by the
eference product but has not been directly studied in a compara-
ive clinical trial with the biosimilar (Danese et al., 2014; Grabowski
t al., 2015). These uncertainties may  be based on a lack of famil-
arity with the scientiﬁc concepts underlying the development and
pproval of biosimilars. In this article, we describe the data required
o establish biosimilarity and emphasize that indication extrapola-
ion is based on true scientiﬁc principles and known mechanism of
ction. We  discuss the regulatory guidelines for indication extrap-
lation and provide speciﬁc examples from biosimilars that are
lready in use in oncology, as well as biosimilars that are in devel-
pment.
. Regulatory requirements to demonstrate biosimilarity
The regulatory requirements for biosimilars approval are gen-
rally similar across guidelines of the European Medicines Agency
EMA), World Health Organization (WHO), and United States
US) Food and Drug Administration (FDA). Although there are
inor differences among the agencies, all require extensive evi-
ence to show that a biosimilar is highly similar to a reference
roduct (European Medicines Agency, 2014; US Food and Drug
dministration, 2015; World Health Organization, 2009). Biosim-
larity approval is granted based on the “totality of evidence,” i.e.,
 comprehensive comparison of the proposed biosimilar and the
eference product with respect to structure, function, animal toxi-
ity, human pharmacokinetics (PK) and pharmacodynamics (PD),
linical immunogenicity, clinical safety, and efﬁcacy (European
edicines Agency, 2014; US Food and Drug Administration, 2015;
orld Health Organization, 2009). Unlike the approval process
or originator biologics that relies heavily on clinical trials to
emonstrate efﬁcacy, safety, and immunogenicity, biosimilars are
pproved based on extensive analytical and nonclinical data and
bridged clinical data; the objective of a biosimilar development
rogram is to demonstrate there are no clinically meaningful
ifferences based on totality of evidence, not to re-establish
eneﬁt. The data required to demonstrate biosimilarity are gen-
rated in a stepwise approach, starting with extensive structural
nd in vitro functional comparisons of the proposed biosimi-
ar and the reference product followed by non-clinical in vivo
nimal studies and clinical studies (European Medicines Agency,
014; US Food and Drug Administration, 2015; World Health
rganization, 2009). Each step of the comparability exercise is used
o determine the level of biosimilarity of the proposed biosimilar
nd the reference product and to address any residual uncer-
ainty about biosimilarity. The structural and in vitro functionallogy/Hematology 104 (2016) 131–137
characterization of the proposed biosimilar and the reference
product is the foundation of a biosimilar development pro-
gram and consist of analyses of primary (i.e., amino acid
sequence), secondary, tertiary, and quaternary structures, includ-
ing aggregation, posttranslational modiﬁcation (e.g., glycosylation,
phosphorylation, and deamidation), intentional chemical modiﬁca-
tion (e.g., PEGylation), and biological activities (US Food and Drug
Administration, 2015). The extent and nature of the non-clinical
in vivo animal studies and clinical studies will depend on the
evidence obtained with each previous step (European Medicines
Agency, 2014; US Food and Drug Administration, 2015; World
Health Organization, 2009). The clinical program should include
a comparative study or studies assessing PK, PD (if feasible), and
safety/immunogenicity. In some cases, these data are sufﬁcient
to support biosimilarity; for example, in the case of Filgrastim
Hexal (Sandoz GmbH, Kundl, Austria) (European Medicines Agency,
2009a), the comparability of efﬁcacy to the reference product ﬁl-
grastim (Neupogen®, Thousand Oaks, CA) based on a PD study
in healthy volunteers was considered acceptable by the commit-
tee for medicinal products for human use of the EMA  (European
Medicines Agency, 2009a). However, if there is a residual uncer-
tainty about possible meaningful differences between the proposed
biosimilar and the reference product, an additional comparative
clinical efﬁcacy, safety, and immunogenicity study or studies may
be required (European Medicines Agency, 2014; US Food and Drug
Administration, 2015; World Health Organization, 2009; Baer Ii
et al., 2014). In evaluating biosimilarity of a proposed biosimilar
to a reference product, regulatory agencies will consider the over-
all research and development program, from analytical through
clinical trial data (European Medicines Agency, 2014; US Food and
Drug Administration, 2015; World Health Organization, 2009). The
type and extent of data required to demonstrate biosimilarity may
vary and will be determined on a case-by-case basis (European
Medicines Agency, 2014; US Food and Drug Administration, 2015;
World Health Organization, 2009).
3. Extrapolation of efﬁcacy and safety data from one
indication to another
After similarity with the reference product has been convinc-
ingly demonstrated based on the totality of evidence and the
product is designated a biosimilar product, it is considered sim-
ilar to the reference product in terms of structure, function, PK,
PD, efﬁcacy, safety, and immunogenicity. If the reference product
is licensed to treat multiple therapeutic indications, extrapolation
of indications may  be possible, but has to be scientiﬁcally justiﬁed.
Extrapolation is the approval of a biosimilar for use in an indication
held by the reference product, not directly studied in a compar-
ative clinical trial with the biosimilar. The amount of scientiﬁc
justiﬁcation required to support the extrapolation of indications
may  differ across regulatory agencies (Table 1). For extrapola-
tion to be considered by regulatory agencies such as the EMA,
FDA, and WHO, biosimilarity to the reference product has to be
demonstrated based on a comprehensive comparability exercise
that includes efﬁcacy and safety/immunogenicity in a key indica-
tion, and the clinically relevant mechanism of action and receptors
involved in each indication has to be the same (Table 1) (European
Medicines Agency, 2014; US Food and Drug Administration, 2015;
World Health Organization, 2009). If the mechanisms of action or
receptors involved are different, additional data (e.g., PD measures)
may be required to justify extrapolation of indication (European
Medicines Agency, 2014; World Health Organization, 2009).
Extrapolation is essential to the concept of biosimilarity. The
EMA  states, “The primary rationale for data extrapolation is to avoid
unnecessary studies in the target population for ethical reasons,
G. Curigliano et al. / Critical Reviews in Oncology/Hematology 104 (2016) 131–137 133
Table  1
Comparison of regulatory guidelines for extrapolation of indications.
European Medicines Agency (2014) US Food and Drug Administration (2015) World Health Organization (2009)
General —Extrapolation could be acceptable with
appropriate scientiﬁc justiﬁcation
—Extrapolation should be based on sufﬁcient
scientiﬁc justiﬁcation
—If extrapolation is intended, a detailed
scientiﬁc discussion on the beneﬁt/risk should
be provided
—Extrapolation should be considered in light
of the totality of data from the biosimilar
comparability testing
—Efﬁcacy and safety tested in most sensitive
indication to detect clinically meaningful
differences in safety (including
immunogenicity) and efﬁcacy
—Efﬁcacy and safety tested in most sensitive
indication
—The  studied therapeutic indication should be
sensitive for differences in all relevant aspects
of safety/efﬁcacy
—Non-inferiority study design may  not
support extrapolation, especially from low
dose to higher dose
Mechanism of action —The reference product interacts with several
receptors
—Target/receptors involved for each relevant
activity/function
—The clinically relevant mechanism of action
and/or receptors involved
—The  reference product has more than one
active site/intracellular signaling pathway
—Binding, dose/concentration response and
pattern of molecular signaling pathway
—Product structure and target/receptor
interactions
—Location and expression of the
target/receptors
Safety/efﬁcacy —Extrapolation of immunogenicity from the
studied indication/route of administration to
other uses require justiﬁcation
—Pharmacokinetics and bio-distribution —Sufﬁcient characterization of safety and
immunogenicity with no unique/new safety
issues expected
—Patient-related factors (co-medications,
comorbidities, immunological status)
—Immunogenicity in different patient
populations
—Immunogenicity should be evaluated in
patients with the highest risk for immune
response
—Disease-related factors (e.g., lysis of tumor —Differences in expected toxicities
or tha
ess
f
t
t
s
e
p
i
i
f
p
F
i
t
i
t
m
r
D
s
t
e
t
4
o
g
b
i
l
4
(cells)
—Any fact
effectiven
or efﬁciency and to allocate resources to areas where studies are
he most needed” (European Medicines Agency, 2013). Replicating
he efﬁcacy and safety data of the reference product is considered
cientiﬁcally not essential and sometimes even unethical (Weise
t al., 2012).
If a proposed biosimilar is truly highly similar to the reference
roduct, it is expected that all aspects of its therapeutic effects,
ncluding efﬁcacy, safety, and immunogenicity, would also be sim-
lar. This principle is already applied for small-molecule generics,
or which demonstration of PK bioequivalence to the reference
roduct is usually sufﬁcient to conclude therapeutic equivalence.
or biosimilars, extrapolation of indications is appropriate if there
s sufﬁcient scientiﬁc justiﬁcation and based on the data from
he entire development program. If extrapolation of clinical data
s intended, the clinical study/studies should be conducted in a
herapeutic indication that is sensitive enough to detect clinically
eaningful differences between the proposed biosimilar and the
eference product (European Medicines Agency, 2014; US Food and
rug Administration, 2015; World Health Organization, 2009). It
hould be noted that the clinical program is only one component of
he comparability exercise and its goal is to conﬁrm the similarity
stablished by the structural and functional characterization and
o address any residual uncertainty pertaining to biosimilarity.
. Extrapolation of indication for approved biosimilars in
ncology
Several biosimilars approved for cancer treatment have been
ranted approval for all indications held by the reference product
ased extrapolation of efﬁcacy and safety data. The following cases
llustrate the scientiﬁc data needed for demonstration of biosimi-
arity and extrapolation of indication..1. Filgrastim
Filgrastim (Neupogen), a granulocyte-colony stimulating factor
G-CSF), is widely used in oncology to prevent chemotherapy-t may  affect safety or
induced neutropenia (Amgen Inc., 1991). Filgrastim is also
approved for treatment in patients with acute myeloid leukemia,
severe chronic neutropenia, or undergoing bone marrow transplan-
tation or peripheral blood progenitor cell collection and engraft-
ment (Amgen Inc., 1991). Several biosimilars to ﬁlgrastim have
been approved in the European Union (Biograstim®/Filgrastim
ratiopharm/Ratiograstim®/TevaGrastim® [Teva LTD, Castleford,
UK]; Zarzio® [Sandoz, Holzkirchen, Germany]; Nivestim® [Hos-
pira, Lake Forest, IL]), and recently in the United States (Zarzio®
[Sandoz]) for all indications of the reference product (Neupogen)
(Gascon et al., 2013). The extrapolation of indications for all ﬁl-
grastim biosimilars was justiﬁed based on (i) overall data from the
comparability exercise that included head-to-head comparisons to
the reference product using analytical methods showing similar
molecular structure and in vitro function, PK studies showing simi-
lar exposure, and PD studies showing effect on absolute neutrophil
and CD34+ cell counts in healthy volunteers, and efﬁcacy and safety
(including immunogenicity) studies in patients with cancer; and
(ii) the single mechanism of action of ﬁlgrastim, i.e., binding to
G-CSF receptor and mediating the same biological activity (stim-
ulation of bone marrow cells) (Gascon, 2012). Although biosimilars
to G-CSF were approved by EMA  for all indications held by the
reference product, due to insufﬁcient long-term safety and efﬁ-
cacy data, some concerns about their use for peripheral blood stem
cell mobilization in healthy donors have been raised by the World
Marrow Donor Association and the European Bone Marrow Trans-
plantation Association (Schmitt et al., 2014; Shaw et al., 2011). A
recent pooled analysis of ﬁve post-approval studies (N = 1302) of
the ﬁlgrastim biosimilar Zarzio demonstrated that severe or febrile
neutropenia occurred within the range observed for the reference
product and the safety proﬁle was  consistent with that of the refer-
ence product, including in healthy stem cell donors (Gascon et al.,
2013; Schmitt et al., 2014). The extrapolation of indications for
the ﬁlgrastim biosimilars was  based on the totality of evidence
that demonstrated high similarity between ﬁlgrastim biosimilars
and the reference product in terms of quality, safety, and efﬁcacy,
and the single mechanism of action; this was  further supported
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y results from post-approval studies (Gascon et al., 2013; Schmitt
t al., 2014).
.2. Erythropoiesis-stimulating agents
Erythropoiesis-stimulating agents (ESAs), including epoetin
lfa (Epogen® [Amgen]; Procrit®/Eprex® [Janssen, Raritan, NJ]),
nd darbepoetin alfa (Aranesp® [Amgen]), are approved for the
reatment of anemia induced by chronic renal failure or cancer
hemotherapy (Niederwieser and Schmitz, 2011). Two  epoetin
iosimilars have been approved in the European Union and those
re marketed by different license holders: HX575 (Epoetin alfa
exal® [Hexal]; Abseamed® [Medice, Iselohn, Germany]; Binocrit®
Sandoz]) and SB309 (Retacrit® [Hospira]; Silapo® [Stada, Bad Vil-
el, Germany]) (Niederwieser and Schmitz, 2011). Biosimilarity for
X575 and SB309 was established based on the comparison exer-
ise with Eprex as the reference product. Approval was  granted for
ll indications of the reference product based on the data from the
ntire research and development program, and the similar mecha-
ism of action of epoetin across all approved indications (European
edicines Agency, 2007a,b). For HX575, although the clinical study
n cancer patients did not allow any conclusion on whether the
fﬁcacy of HX575 administrated subcutaneously (SC) was  compa-
able to that of Eprex, extrapolation of data – for anemia in patients
ith chronic renal failure to cancer patients – was based on the
ntire comparability exercise between HX575 and Eprex (European
edicines Agency, 2007a). The data included demonstration of
he comparable efﬁcacy after intravenous (IV) administration in
atients with chronic renal failure, the similar PK/PD proﬁle after
epeat-dose administration of SC HX575 and Eprex in healthy sub-
ects, the similar PK/PD proﬁle after IV administration of HX575
nd Eprex in healthy subjects and the safety proﬁles (including
mmunogenicity) of HX575 and Eprex in cancer patients were com-
arable (European Medicines Agency, 2007a). For SB309, although
 study comparing SC administration of SB309 and Eprex has not
een conducted, SB309 was approved for SC administration in can-
er patients based on the entire comparability exercise between
B309 and Eprex (European Medicines Agency, 2007b). The data
ncluded demonstration of the similar efﬁcacy and PK/PD proﬁle
fter IV administration in patients with renal failure, the similar PK
roﬁle after SC administration that may  suggest similar efﬁcacy for
C use and the generally similar safety proﬁles with no new safety
including immunogenicity) concerns after IV administration of
B309 in cancer patients (European Medicines Agency, 2007b).
verall, the extrapolation of indications for epoetin biosimilars was
ased on the totality of evidence that included similar structure and
unction, comparable PD effects (i.e., stimulation of reticulocytes),
omparable efﬁcacy in patients with renal anemia, and comparable
afety between the epoetin biosimilars and their reference product,
nd the similar mechanism of action in all approved indications.
. Biosimilar monoclonal antibodies in development for
ncology
Recognizing the highly complex structure of mAbs, the EMA
ublished additional guidelines speciﬁc for mAbs to complement
he original EMA  guidelines for the development of biosimilars
European Medicines Agency, 2012). These guidelines state that
xtrapolation of clinical safety and efﬁcacy data to other indi-
ations approved for the reference mAb  is possible based on
he results of the overall evidence provided in the comparability
xercise and with scientiﬁc justiﬁcation. A request for indication
xtrapolation should be supported by scientiﬁc rationale on the
echanism of action and the receptors involved in each indica-
ion. If the mechanism of action is different or unknown, otherlogy/Hematology 104 (2016) 131–137
relevant data should be provided to support extrapolation of
indications (European Medicines Agency, 2012). In the oncology
setting, because the preferred endpoints to establish anticancer
activity, i.e., progression-free/disease-free survival or overall sur-
vival, may  not be feasible or sensitive enough to establish similar
efﬁcacy of the biosimilar and the reference mAbs, the EMA  rec-
ommends using a clinical endpoint that measures activity as a
primary endpoint (e.g., overall response rate or pathological com-
plete response) (European Medicines Agency, 2012). To enable
detection of potential product-related differences and minimize
the risk for unpredictable immune responses, extrapolation of clini-
cal data is recommended from a population that is potentially more
homogenous and not immune-compromised versus a population
that is less homogenous and immune-compromised (European
Medicines Agency, 2012).
5.1. Trastuzumab
Trastuzumab (Herceptin® [Genentech/Roche]), a humanized
recombinant mAb  directed at the human epidermal growth factor
receptor 2 (HER2), is indicated for the treatment of HER2-positive
breast cancer in the adjuvant and metastatic setting, and for the
treatment of HER2-positive metastatic gastric or gastroesophageal
junction adenocarcinoma (Genentech Inc., 1998). The composi-
tion of matter patent covering trastuzumab marketed in Europe
(Herceptin [Roche]) expired in 2014; the last composition of
matter patent in the United States (Herceptin [Genentech]) will
expire in 2019 (Philippidis, 2014). Biosimilars to trastuzumab are
being developed and many are in late-stage clinical development
(Table 2); all are being conducted in patients with metastatic breast
cancer (MBC) or early breast cancer (EBC). Extrapolation from
metastatic setting to adjuvant setting and vice versa could be jus-
tiﬁed if biosimilarity is established based on the totality of the
evidence and the mechanism of action is proved to be the same in
these indications. Worldwide, two  biosimilars to trastuzumab have
been approved: one by the Korean Ministry of Food and Drug Safety,
which is marketed in South Korea (Herzuma® [Celltrion, Incheon
City, Republic of Korea]) (Generics and Biosimilars Initiative (GaBI)
Online, 2014a), and the other by the Drugs Controller General of
India, which is marketed under two different brand names in India
(HertrazTM [Mylan, Mumbai, India] and CANMAbTM [Biocon, Ban-
galore, India]) (Generics and Biosimilars Initiative (GaBI) Online,
2014b,c). These biosimilars have been approved for all indications
held by the reference product (Herceptin). It should be noted that
biosimilars approved in India might not meet the stringent reg-
ulatory requirements for establishing biosimilarity as outlined by
EMA, FDA, or WHO.
5.2. Bevacizumab
Bevacizumab (Avastin® [Genentech and Roche]) is a recom-
binant humanized mAb  that is directed at the human vascular
endothelial growth factor (VEGF) (Genentech Inc., 2004; European
Medicines Agency, 2009c). Bevacizumab is approved in the
European Union and United States as a component of combina-
tion therapy for the treatment of metastatic colorectal cancer,
metastatic or recurrent non-squamous non-small-cell lung cancer,
and metastatic renal cell carcinoma, as well as cervical, platinum-
resistant recurrent epithelial ovarian, fallopian tube, and primary
peritoneal cancers. In addition, bevacizumab is approved in the
European Union as a component of combination therapy for the
treatment of metastatic breast cancer and in the Unites States as a
single agent for the treatment of glioblastoma in adults with pro-
gressive disease following prior therapy. Approved indications may
vary in other countries. The composition of matter patent cover-
ing bevacizumab marketed in the United States (Genentech) will
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Table  2
Biosimilar monoclonal antibodies in development for oncology with registered phase III trials.a
Biosimilar name Company Indication tested Status Estimated primary completion dateb
Biosimilars to trastuzumab (Herceptin® , Genentech)
BCD-022 Biocad HER2 + MBC Ongoing, not recruiting March 2015
PF-05280014 Pﬁzer HER2 + MBC  Currently recruiting October 2017
HER2 + EBC (Jacobs et al., 2015) Currently recruiting December 2016
ABP  980 Amgen HER2 + EBC Currently recruiting December 2016
CT-P6  Celltrion HER2 + MBC  (Im et al., 2013) Ongoing, not recruiting December 2017
HER2 + EBC Currently recruiting June 2019
SB3-G31-BC Samsung Bioepis HER2 + early or locally advanced BC Currently recruiting January 2016
Hercules/Myl1401O Mylan GmbH HER2 + MBC Ongoing, not recruiting January 2016
Biosimilars to bevacizumab (Avastin® , Genentech/Roche)
BCD-021 Biocad NSCLC (Filon et al., 2015) Ongoing, not recruiting November 2015
PF-06439535 Pﬁzer NSCLC Currently recruiting July 2017
ABP  215 Amgen NSCLC Ongoing, not recruiting July 2015
Biosimilars to rituximab (Rituxan® , Genentech/Biogen Idec; MabThera® , Roche)
BCD-020 Biocad IndolentNHL (Alexeev et al., 2014) Currently recruiting December 2015
RA Ongoing, not recruiting July 2015
PF-05280586 Pﬁzer FL Currently recruiting November 2016
RA (Williams et al., 2015) Ongoing, not recruiting August 2015
ABP  798 Amgen RA Ongoing Not available
NHL Ongoing Not available
GP2013 Sandoz FL Ongoing, not recruiting December 2017
RA Currently recruiting December 2016
CT-P10  Celltrion FL Currently recruiting February 2017
FL  Not yet recruiting March 2018
RA (Yoo et al., 2013) Currently recruiting January 2017
RTXM83 mAbxience DLBCL Currently recruiting May  2016
BC, breast cancer; DLBCL, diffuse large B-cell lymphoma; EBC, early breast cancer; FL, follicular lymphoma; HER2, human epidermal growth factor receptor; MBC, metastatic
b RA, rh
rm or
e
(
b
a
d
b
5
M
d
i
R
t
l
i
I
t
(
i
2
d
i
r
l
a
a
f
t
t
(
B
treast cancer; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small-cell lung cancer, 
a Registered on ClinicalsTrials.gov, the International Clinical Trials Registry Platfo
b Final data collection date for primary outcome measure.
xpire in 2019; the last composition of matter patent in Europe
Roche) will expire in 2018 (Philippidis, 2014). Only a few potential
iosimilars to bevacizumab are in late-stage clinical development
nd have a registered phase III trial (Table 2); all are being con-
ucted in patients with non-small-cell lung cancer. At this time, no
iosimilars to bevacizumab are approved.
.3. Rituximab
Rituximab (Rituxan® [Genentech/Biogen Idec, US] and
abThera® [Roche, EU]) is a chimeric murine-human mAb
irected at the CD20 antigen of B cells. Rituximab is unique as it
s approved for both oncology and anti-inﬂammatory indications.
ituximab, in combination with glucocorticoids, is indicated for
he treatment of non-Hodgkin’s lymphoma, chronic lymphocytic
eukemia, rheumatoid arthritis and granulomatosis with polyangi-
tis and microscopic polyangiitis in adult patients (Biogen Idec
nc., 1997; European Medicines Agency, 2009b). The composi-
ion of matter patent covering rituximab marketed in Europe
MabThera) expired in 2013; the last composition of matter patent
n the United States (Rituxan) will expire in 2018 (Philippidis,
014). Several biosimilars to rituximab are in late-stage clinical
evelopment (Table 2). Comparative clinical studies for ritux-
mab biosimilars are conducted in various indications, including,
heumatoid arthritis, diffuse large B-cell lymphoma, and follicular
ymphoma. Extrapolation of indication for rituximab may be
llowed from non-malignant setting (e.g., rheumatoid arthritis) to
n oncology setting, from oncology setting to autoimmune disease,
rom single-agent to combination therapy, or from combination
o single-agent if it is scientiﬁcally justiﬁed. Recently, a biosimilar
o rituximab has been approved by the Russian Ministry of Health
AcellbiaTM [Biocad, Saint Petersburg, Russia]) (Generics and
iosimilars Initiative (GaBI) Online, 2014d). It should be noted that
he biosimilars in Russia may  not meet the stringent regulatoryeumatoid arthritis.
 the European Union Clinical Trials Register.
requirements for establishing biosimilarity as outlined by EMA,
FDA, or WHO.
Approval of biosimilar mAbs may  help preventing the risk of
drug shortages, i.e., the supply of the reference product not meet-
ing its demand, which could have a devastating effect on the life
of patients with cancer (Li et al., 2015). The accelerated develop-
ment program of biosimilar mAbs that relies on extrapolation may
minimize some of the potential causes of drug shortages, including
manufacturing related issues and increased demand. The availabil-
ity of high-quality, safe, and effective biosimilars, developed by
reliable manufacturers that follow the stringent regulatory require-
ments of EMA, FDA, or WHO, may  ensure broader patient access to
biologic therapies while preventing potential drug supply shortage.
6. Conclusions
As some of the composition of matter patents covering oncology
biologic mAbs have expired or will expire in the upcoming years,
approval of biosimilar mAbs for oncology indications is expected.
Biosimilarity is established based on comprehensive comparability
analytical, functional, non-clinical, and clinical studies. Extrapo-
lation of indication is an integral part of the biosimilar concept;
it allows manufacturers to make biologic therapies more broadly
accessible within a tailored development program. Extrapolation of
indication must be scientiﬁcally justiﬁed and is based on the total-
ity of evidence from the comparability exercise with the reference
product. When seeking extrapolation of indications, pivotal clini-
cal studies to assess efﬁcacy and safety (including immunogenicity)
should be conducted in the most-sensitive patient population,
using endpoints that can detect any clinically meaningful differ-
ences between the proposed biosimilar and the reference product.
The goal of the clinical program is not to re-establish patient beneﬁt
but to conﬁrm the similarity established by the structural and func-
tional characterization. Biosimilars uptake increased dramatically
across Europe since their introduction to the market, though the
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ptake varies signiﬁcantly among different countries (IMS  Institute
or Healthcare Informatics, 2014). Based on the European expe-
ience with biosimilars over the past few years, biosimilars have
unctioned, as expected, similar to the originator biologics, includ-
ng in indications that were licensed based on extrapolation.
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